Qian Xu, Coordes Annekatrin, Kaufmann Andreas M, Albers Andreas E
Department of Otolaryngology, Head and Neck Surgery, Charité - Medical University of Berlin, Benjamin Franklin Campus, D-12200 Berlin, Germany; School of Basic Medical Science, Zhejiang Provincial Key Laboratory of Medical Genetics, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China.
Department of Otolaryngology, Head and Neck Surgery, Charité - Medical University of Berlin, Benjamin Franklin Campus, D-12200 Berlin, Germany.
Oncol Lett. 2016 Nov;12(5):3429-3434. doi: 10.3892/ol.2016.5100. Epub 2016 Sep 7.
Despite the development of novel multimodal treatment combinations in advanced oropharyngeal squamous cell carcinoma (OSCC), outcomes remain poor. The identification of specifically validated biomarkers is required to understand the underlying molecular mechanisms, to evaluate treatment efficiency and to develop novel therapeutic targets. The present study, therefore, examined the presence of aldehyde dehydrogenase family 1 member A1 (ALDH1A1) and high mobility group box 1 (HMGB1) expression in primary OSCC and analyzed the impact on survival time. In 59 patients with OSCC, the expression of ALDH1A1, p16 and HMGB1, and their clinicopathological data were analyzed. HMGB1 positivity was significantly increased in patients with T1-2 stage disease compared with T3-4 stage disease (P<0.001), whereas ALDH1A1 positivity was not. ALDH1A1 tumors showed significantly lower differentiation than ALDH1A1 tumors (P=0.018). Multivariate analysis showed that ALDH1A1 positivity (P=0.041) and nodal status (N2-3) (P=0.036) predicted a poor prognosis. In this patient cohort, ALDH1A1 and nodal status were identified as independent predictors of a shorter overall survival time. The study results, therefore, provide evidence of the prognostic value of ALDH1A1 as a marker for cancer stem cells and nodal status in OSCC patients.
尽管在晚期口咽鳞状细胞癌（OSCC）中已开发出新型多模式治疗组合，但治疗效果仍然不佳。需要鉴定经过专门验证的生物标志物，以了解潜在的分子机制、评估治疗效果并开发新的治疗靶点。因此，本研究检测了原发性OSCC中醛脱氢酶家族1成员A1（ALDH1A1）和高迁移率族蛋白B1（HMGB1）的表达情况，并分析了其对生存时间的影响。对59例OSCC患者的ALDH1A1、p16和HMGB1表达及其临床病理数据进行了分析。与T3-4期疾病患者相比，T1-2期疾病患者的HMGB1阳性率显著升高（P<0.001），而ALDH1A1阳性率则无显著差异。ALDH1A1阳性肿瘤的分化程度明显低于ALDH1A1阴性肿瘤（P=0.018）。多变量分析显示ALDH1A1阳性（P=0.041）和淋巴结状态（N2-3）（P=0.036）预示着预后不良。在该患者队列中，ALDH1A1和淋巴结状态被确定为总生存时间较短的独立预测因素。因此，研究结果为ALDH1A1作为OSCC患者癌症干细胞标志物和淋巴结状态的预后价值提供了证据。
